Before launching into development, Dr Erwin Blomsma took a research-first approach, surveying veterinarians, analysing clinic data, and identifying a major gap in canine cancer care. He shares how this market insight built investor conviction and informed a therapy ultimately creating a pathway to longer, healthier lives for dogs with bladder cancer.








